Clinical Trials Logo

BRAF V600E clinical trials

View clinical trials related to BRAF V600E.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05304546 Not yet recruiting - Metastatic Melanoma Clinical Trials

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

MK3475-C01
Start date: June 2023
Phase: Phase 2
Study type: Interventional

This study will enroll metastatic (Stage IV or inoperable stage III) melanoma (MM) patients carrying a BRAF V600E/K mutation with confirmed primary resistance to standard of care immunotherapy (single agent PD-1 or a combination of CTLA-4/PD-1 blockade). Patients must be naïve to therapy with BRAF+MEK inhibitors, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.